QGEN
Qiagen N.V.
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$43.55
−0.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1B | 2.1B | 2.0B | 2.0B | 2.1B |
| Cost of Revenue | 801.8M | 798.5M | 1.0B | 731.6M | 757.0M |
| Gross Profit | 1.3B | 1.3B | 967.4M | 1.2B | 1.4B |
| Operating Expenses | |||||
| R&D Expense | 194.7M | 187.5M | 193.5M | 198.5M | 189.9M |
| SG&A Expense | 586.1M | 583.7M | 564.4M | 579.2M | 603.9M |
| General & Admin Expense | 121.3M | 125.7M | 113.4M | 119.3M | 129.7M |
| Selling & Marketing Expense | 464.8M | 458.0M | 450.9M | 459.9M | 474.2M |
| Other Expenses | (14.4M) | — | 111.8M | 46.1M | 59.3M |
| Total Operating Expenses | 766.4M | 771.2M | 869.6M | 823.8M | 853.1M |
| Cost and Expenses | 1.6B | 1.6B | 1.9B | 1.6B | 1.6B |
| Operating Income (EBIT) | 532.1M | 520.3M | 97.7M | 409.9M | 531.5M |
| Non-Operating | |||||
| Interest Income | 55.0M | 64.3M | 68.0M | 79.0M | 32.8M |
| Interest Expense | 39.4M | 33.3M | 43.8M | 53.4M | 58.4M |
| Net Interest Income | 15.6M | 31.1M | 24.2M | 25.6M | (25.6M) |
| Other Non-Op Income/Expense | (70.3M) | (30.0M) | 23.4M | 19.9M | (18.9M) |
| Non-Operating Income (excl Interest) | 30.8M | (3.2M) | (67.3M) | (73.3M) | (39.5M) |
| EBT (Pre-Tax Income) | 461.8M | 490.3M | 121.1M | 429.8M | 512.6M |
| Income Tax Expense | 52.5M | 65.4M | 37.6M | 88.5M | 89.4M |
| Bottom Line | |||||
| Net Income | 409.3M | 424.9M | 83.6M | 341.3M | 423.2M |
| Earnings from Cont. Ops | 409.3M | 424.9M | 83.6M | 341.3M | 423.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 409.3M | 424.9M | 83.6M | 341.3M | 423.2M |
| Per Share | |||||
| Basic EPS | $1.95 | $2.04 | $0.39 | $1.67 | $2.08 |
| Diluted EPS | $1.95 | $2.04 | $0.38 | $1.65 | $2.05 |
| Revenue Per Share | $10.18 | $10.05 | $9.14 | $9.04 | $9.70 |
| Shares | |||||
| Basic Shares Outstanding | 206.3M | 207.9M | 216.4M | 217.5M | 220.7M |
| Diluted Shares Outstanding | 207.8M | 207.9M | 218.5M | 217.5M | 223.2M |
| Profitability Metrics | |||||
| EBITDA | 736.2M | 717.3M | 368.3M | 688.6M | 779.4M |
| D&A | 234.9M | 193.7M | 203.3M | 205.3M | 208.4M |
| EBIT | 501.3M | 523.5M | 165.0M | 483.2M | 571.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026